Immune‐related adverse events of a PD‐L1 inhibitor plus chemotherapy versus a PD‐L1 inhibitor alone in first‐line treatment for advanced non–small cell lung cancer: A meta‐analysis of randomized control trials-Reference-Cited by-同舟云学术

Immune‐related adverse events of a PD‐L1 inhibitor plus chemotherapy versus a PD‐L1 inhibitor alone in first‐line treatment for advanced non–small cell lung cancer: A meta‐analysis of randomized control trials

Published:2020-10-29 Issue:5 Volume:127 Page:777-786
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Wang Manting¹²³⁴⁵^ORCID,Liang Hengrui¹²³⁴^ORCID,Wang Wei¹²³⁴,Zhao Shen⁶⁷⁸,Cai Xiuyu⁶⁷⁸⁹,Zhao Yi¹²³⁴,Li Caichen¹²³⁴,Cheng Bo¹²³⁴,Xiong Shan¹²³⁴,Li Jianfu¹²³⁴^ORCID,He Jianxing¹²³⁴^ORCID,Liang Wenhua¹²³⁴^ORCID

Affiliation:

1. Department of Thoracic Surgery and Oncology First Affiliated Hospital of Guangzhou Medical University Guangzhou China

2. State Key Laboratory of Respiratory Disease Guangzhou China

3. National Clinical Research Center for Respiratory Disease Guangzhou China

4. Guangzhou Institute of Respiratory Health Guangzhou China

5. Nanshan SchoolClinical Medicine DepartmentGuangzhou Medical University Guangzhou China

6. Department of Medical Oncology Sun Yat‐Sen University Cancer Center Guangzhou China

7. State Key Laboratory of Oncology in South China Guangzhou China

8. Collaborative Innovation Center for Cancer Medicine Guangzhou China

9. Department of General Internal Medicine Sun Yat‐Sen University Cancer Center Guangzhou China

Publisher

Wiley